Robert W. Baird Lowers Thermo Fisher Scientific (NYSE:TMO) Price Target to $639.00

Key Points

• Robert W. Baird lowered its price target on Thermo Fisher from $653 to $639 but kept an "outperform" rating, with the new target implying roughly a 36.85% upside from the previous close.
• Q1 results beat expectations—adjusted EPS $5.44 vs. $5.25 and revenue $11.01B—and management raised FY2026 guidance to $24.640–25.120 EPS, yet the stock fell about 9.2% as investors focused on weak organic growth and mixed segment trends.
• Analyst and ownership backdrop: consensus is a "Moderate Buy" with an average target near $630.55 (majority Buy ratings), insiders have trimmed small positions (CEO sold 5,000 shares), and institutions own roughly 89% of the stock.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price objective dropped by stock analysts at Robert W. Baird from $653.00 to $639.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical research company's stock. Robert W. Baird's target price suggests a potential upside of 36.85% from the company's previous close.

Several other research firms have also recently weighed in on TMO. TD Cowen cut their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a research report on Friday, January 30th. Wells Fargo & Company set a $683.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 30th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a "buy" rating in a research note on Friday, January 9th. Finally, UBS Group restated a "neutral" rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $630.55.

Thermo Fisher Scientific Stock Down 9.2%

TMO stock opened at $466.93 on Friday. The stock's fifty day simple moving average is $499.83 and its two-hundred day simple moving average is $549.98. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $643.99. The stock has a market cap of $173.52 billion, a P/E ratio of 26.32, a P/E/G ratio of 2.66 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same quarter in the previous year, the firm earned $5.15 earnings per share. The business's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts expect that Thermo Fisher Scientific will post 24.68 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the sale, the executive vice president owned 20,752 shares in the company, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the stock. High Note Wealth LLC grew its position in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $29,000. Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Birchwood Financial Partners Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. 89.23% of the stock is currently owned by institutional investors.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Analysts say the pullback may be overdone — TD Cowen reiterated a Buy on TMO, noting solid fundamentals and growth catalysts later in the year, even while trimming its price target. Thermo Fisher Scientific: Stock Pullback Seen as Overdone
• Positive Sentiment: Management raised full‑year 2026 guidance (EPS and revenue range), signaling confidence in medium‑term demand despite a soft organic start to the year. Thermo Fisher Raises 2026 Outlook Despite First-Quarter Organic Revenue Growth Miss
• Neutral Sentiment: Q1 headline results beat estimates — revenue up ~6% YoY to $11.01B and adjusted EPS of $5.44 — which supports the company’s premium valuation narrative. Thermo Fisher Scientific Reports First Quarter 2026 Results
• Neutral Sentiment: Company flagged modest inflation risk tied to Middle East tensions and noted uneven demand across analytical instruments and specialty diagnostics versus strength in lab products and biopharma services. Thermo Fisher Flags 'Modest Inflation' Risk Amid Middle East Tensions
• Negative Sentiment: Market focus landed on weak underlying organic growth and mixed segment trends despite beats; that narrative drove the largest immediate selling pressure after the print. Why Thermo Fisher (TMO) Stock Is Nosediving
• Negative Sentiment: Peer/sector spillover: competitors such as 10x Genomics sold off after TMO’s mixed tone, amplifying downside in life‑science tooling names. Why 10x Genomics (TXG) Shares Are Trading Lower Today
• Negative Sentiment: Broader market and tech weakness on the day (risk‑off flow) intensified selling pressure on cyclical/health‑tech names, compounding stock declines. Stocks Settle Lower on US-Iran Stalemate

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.